Next-generation U-Net Encoder: Decoder for accurate, automated CTC detection from images of peripheral blood nucleated cells stained with EPCAM and DAPI.

T Tim Crook (Cromwell Hospital, London, United Kingdom) M Massimo Cristofanilli (Weill-Cornell Medicine, New York–Presbyterian Hospital, New York) S Sewanti Atul Limaye (Medical & Precision Oncology, Clinical and Translational Oncology Research, Sir HN Reliance Foundation, Mumbai, India) A Ashok K. Vaid (Medanta, The Medicity, Gurugram, India) A Anantbhushan Ranade (Avinash Cancer Clinic, Pune, India) A Amit Dilip Bhatt (Avinash Cancer Clinic, Pune, India) K Kefah Mokbel (London Breast Institute, London, United Kingdom) V Vineet Datta (Datar Cancer Genetics, Nashik, India) A Ashwini Ghaisas (Datar Cancer Genetics, Nashik, India) A Atreyee Saha (Institute of Physiological Chemistry and Pathobiochemistry University of Münster Münster Germany) R Rohit Chougule (Datar Cancer Genetics Limited, Nashik, India) S Snehal Golar (Datar Cancer Genetics, Nashik, India) D David Reismann (Datar Cancer Genetics Europe GmbH, Bayreuth, Germany) D Darshana Patil (Datar Cancer Genetics, Nashik, India) R Rajan Datar (Datar Cancer Genetics, Nashik, India)

Abstract

3061 Background: Direct circulating tumor cell (CTC) detection is a promising biomarker for early cancer detection and monitoring. Traditional fluorescence microscopy and AI-driven methods have limitations such as subjectivity and labor-intensiveness. We developed a deep-learning pipeline using a U-Net–type encoder–decoder architecture for precise pixel-level CTC discrimination in peripheral blood nucleated cells (PBNCs). This method preserves morphological and fluorescence details, overcoming convolutional neural network (CNN) limitations by maintaining fine features through skip connections for better discrimination. We present specificity and sensitivity data from a case-control study. Methods: We collected 5 ml of peripheral blood in EDTA tubes from 1383 asymptomatic healthy volunteers (744, 54% male; 639, 46% females with mean age of 49 [(20 to 93) yrs], 38 individuals diagnosed with non-malignant conditions including prostatitis, PCOD and acute pancreatitis, and 143 individuals recently diagnosed with surgically resectable early stage cancers (Stage 1/ 2) - Head and Neck (N=50, 35%), Breast (N=31, 22%), Colorectal (N=17, 12%), Pancreas (N=8, 6%), Prostate (N=8, 6%), Lung (N=5, 3%), Ovary (N=5, 3%) others (N=19, 13%). Nucleated cells were isolated from the samples after RBC lysis and centrifugation and stained with EPCAM and DAPI and set on imaging slides. 60X images were obtained and processed by AI utilizing U-Net–Based Encoder–Decoder Architecture and context discrimination to detect CTCs. The customized U-Net pipeline encodes spatial information through successive convolutional and pooling layers, generating a highly compressed representation of cells in the bottleneck. By employing transposed convolutions in the decoder stage—and incorporating skip connections from the encoder layers—the AI model reconstructs a pixel-wise segmentation mask to identify potential CTCs with cell diameter >10 microns. This approach aims to surpass existing methods that rely on bounding-box–based detection by offering enhanced sensitivity and specificity through end-to-end learned feature extraction. Ground truth annotations were established via expert cytopathology review, and training procedures involved cross-validation to ensure generalizable performance. Results: Analysis of total 1564 samples showed that our U-Net–based model achieved a sensitivity of 89% (95% CI: 88.81) and specificity of 97% (95% CI: 97.98) for detecting CTCs. Performance remained consistent across solid tumors, highlighting the flexibility and adaptability of the architecture in various fluorescence staining conditions. Conclusions: Our U-Net pipeline uses pixel-level segmentation and skip connections to enhance CTC detection accuracy. Integrating fluorescence and morphology, it can streamline cancer screening and disease monitoring.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 3061-3061
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (15)

T

Tim Crook

Cromwell Hospital, London, United Kingdom

M

Massimo Cristofanilli

Weill-Cornell Medicine, New York–Presbyterian Hospital, New York

S

Sewanti Atul Limaye

Medical & Precision Oncology, Clinical and Translational Oncology Research, Sir HN Reliance Foundation, Mumbai, India

A

Ashok K. Vaid

Medanta, The Medicity, Gurugram, India

A

Anantbhushan Ranade

Avinash Cancer Clinic, Pune, India

A

Amit Dilip Bhatt

Avinash Cancer Clinic, Pune, India

K

Kefah Mokbel

London Breast Institute, London, United Kingdom

V

Vineet Datta

Datar Cancer Genetics, Nashik, India

A

Ashwini Ghaisas

Datar Cancer Genetics, Nashik, India

A

Atreyee Saha

Institute of Physiological Chemistry and Pathobiochemistry University of Münster Münster Germany

R

Rohit Chougule

Datar Cancer Genetics Limited, Nashik, India

S

Snehal Golar

Datar Cancer Genetics, Nashik, India

D

David Reismann

Datar Cancer Genetics Europe GmbH, Bayreuth, Germany

D

Darshana Patil

Datar Cancer Genetics, Nashik, India

R

Rajan Datar

Datar Cancer Genetics, Nashik, India